Esperion Therapeutics, Inc.
http://www.esperion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Esperion Therapeutics, Inc.
CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy
The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.
Stock Watch: Biotechs Sell The Family Silver
When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.
Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.
Finance Watch: More Good To Come? CG Oncology Grosses $380m In Year’s First IPO
Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice